08:22 – 08:28 |
Welcome Address Evi Lianidou, PhD, Professor of Analytical Chemistry – Clinical Chemistry, Analysis of Circulating Tumor Cells lab, Dept of Chemistry, University of Athens, Greece |
Plenary Lectures 1: Liquid biopsy from CTCs to ctDNA | |
08:30 – 09:00 | Liquid Biopsy: From Discovery to Clinical Application Klaus Pantel, University Medical Centre Hamburg Eppendorf, Hamburg, Germany |
09:02 – 09:25 | Circulating Tumor Cells: “Metastasis-Initiator Circulating Tumor Cells: One of the keys to understand the biology of the metastatic cascade” Catherine Alix-Panabières, Laboratoire Cellules Circulantes Rares Humaines - LCCRH, Institut de Recherche en Biothérapie - IRB, Hôpital Saint-Eloi - CHRU Montpellier, France |
09:27 – 10:06 | Circulating tumor DNA: “Liquid Biopsy and early detection of cancer” Nicholas Papadopoulos, Professor of Oncology and Pathology, Director of Translational Genetics, Ludwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA |
Plenary Lectures 2: Liquid biopsy in the clinical setting: breast cancer | |
10:08 – 10:40 | CTCs and ctDNA in breast cancer: translational research and real-world applications Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Department of Medicine-Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center Feinberg School of Medicine, Chicago, IL, USA |
10:42 – 11:09 | Clinical applications of liquid biopsy in breast cancer management Jean-Yves Pierga, MD, PhD, Professor of Medical Oncology, at the Institute Curie and University Paris Descartes, Paris, France |
11:11 – 11:33 | PREDICT – An Up-Date on the global pooled analysis on the relevance of early CTC monitoring in patients with advanced breast cancer Wolfgang Janni, Medical Director of the Gynaecological University Hospital Ulm, University of Ulm, Germany |
11:35 – 12:02 | First results from the randomized phase III DETECT III trial regarding the efficacy of lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells Tanja Fehm, Department of Gynecology and Obstetrics, Heinrich Heine University Duesseldorf, Duesseldorf, Germany |
12:04 – 12:30 | Liquid biopsy enters the clinic: challenges ahead Michail Ignatiadis, MD PhD, Assoc. Professor, Université Libre de Bruxelles, Jules Bordet Institute Brussels, Belgium, Chair Breast Cancer Group EORTC |
Plenary Lectures 3: Liquid biopsy in the clinical setting: lung cancer | |
12:32- 12:55 | Personalised medicine for small cell lung cancer: is it getting closer? Caroline Dive, University of Manchester, UK |
12:57- 13:27 | Clinical applications of Liquid biopsy in non-small cell lung cancer Christian Rolfo, MD, PhD, MBA, Dr.hc., Professor and Assoc. Director for Clinical Research, Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, One Gustave Levy Place, Box 1079, New York, NY, 10029, USA |
Plenary Lectures 4: Liquid biopsy in the clinical setting: Prostate, ovarian, head and neck cancer | |
13:30- 14:03 | Liquid biopsy: latest advances in prostate cancer Howard Scher, MD, Medical Oncologist, Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan Kettering Cancer Research, New York, NY, USA |
14:05- 14:31 | Clonal hematopoiesis (CHIP) mutations in liquid biopsies from solid tumors: A diagnostic dilemma Emmanuel Antonarakis, MD, Associate Director for Translational Research and Director of Genitourinary Oncology in HOT Division, University of Minnesota–Masonic Cancer Center, USA |
14:33- 15:02 | Liquid biopsy in head and neck cancer Amanda Psyrri, MD, PhD, Professor, University of Athens Medical School, Attikon University Hospital, Athens, Greece |
15.04 – 15:33 | Current challenges in ovarian cancer: Characterization of single circulating tumor cells and other liquid biopsy analytes for therapeutical approaches Sabine Kasimir-Bauer, University Hospital of Essen, Essen, Germany |
15:35 – 15:58 | Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy María Jose Serrano Fernández, PhD, Scientific Director of Liquid Biopsies Division, Liquid Biopsies & Cancer Interception group, GENyO Centre/ Hospital Virgen de las Nieves, Granada, Spain |
16:00 – 16:29 | Analysis of large blood volumes: enhancing CTC-based liquid biopsies for research and clinical applications Nikolas Stoecklein, Heinrich Heine University, Düsseldorf, Germany |
Plenary Lectures 5: Liquid biopsies: Circulating tumor DNA analysis in clinical practice | |
16:31 – 16:57 | The potential of ctDNA in clinical practice: From single gene to genome wide approaches Helen Heitzer, Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria |
16:59 – 17:34 | Deciphering open chromatin regions and epigenetic traces from plasma DNA Michael Speicher, Institute of Human Genetics, Medical University of Graz, Austria |
17:37 – 18:04 | Clinical Utility of Cell Free MicroRNA Signatures in Cancer Patients Plasma Dave Hoon, Director Translational Molecular Medicine, SJCI PHS, Santa Monica CA, USA |
18:15 – 19:30 | Q and A: Liquid Biopsy applications in Clinical practice Moderator: Evi Lianidou, President Hellenic Society of Liquid Biopsy All speakers Closing remarks |